Diagnosing Pseudomonas aeruginosa: Cultures and Biofilm Detection

Getting the diagnosis right is the foundation of treating Pseudomonas aeruginosa infections effectively. The wrong antibiotic — or the right antibiotic at the wrong dose — can fail to control this pathogen and accelerate the development of resistance. This article walks through how laboratories identify P. aeruginosa, how they test its antibiotic susceptibility, and how emerging techniques detect the biofilm communities that make this organism so difficult to treat.

Table of Contents

1. Specimen Collection: Getting the Right Sample
2. Standard Aerobic Culture and Growth Characteristics
3. Selective Media: Cetrimide Agar
4. Pigment Identification: Pyocyanin and Pyoverdine
5. The Antipseudomonal Antibiogram
6. Biofilm Detection: Crystal Violet and Beyond
7. Bronchoalveolar Lavage for VAP Diagnosis
8. Molecular Typing: PFGE and Whole Genome Sequencing
9. PCR for Resistance Determinants
10. Key Research Papers
11. Featured Videos

Specimen Collection: Getting the Right Sample

The diagnostic process begins with collecting the right specimen from the right site before antibiotics are started. P. aeruginosa is a hardy organism that grows readily from properly collected samples, but several principles must be followed:

• Blood cultures: In suspected bacteremia, two or three sets (aerobic and anaerobic) drawn from separate venipuncture sites before any antibiotic is administered. For ICU patients with central venous catheters, one set from the catheter and one from a peripheral vein can help determine whether the catheter is the source.
• Sputum: In community-acquired respiratory infections, spontaneous sputum is acceptable if collected correctly (the patient must have brushed teeth, rinsed with water, and produced a deep productive specimen — not saliva). In ventilated patients, endotracheal aspirate or BAL (see below) is preferred for VAP.
• Wound cultures: Swab cultures of wound surfaces are superficial and often reflect colonization rather than true infection. Quantitative biopsy cultures (homogenized tissue, plated at dilutions to count CFU per gram) are the gold standard for distinguishing colonization from invasive wound infection. The threshold of 100,000 CFU/g indicates invasive infection.
• Urine: Midstream clean-catch in ambulatory patients, catheter specimen from the catheter port (not the collection bag) in catheterized patients. Counts above 100,000 CFU/mL are conventionally diagnostic of UTI, though in symptomatic patients lower counts may be significant.

Pre-antibiotic sampling is critical: even a single dose of an antipseudomonal agent can suppress growth in culture and cause a false-negative result, particularly from blood cultures. (PMID: 27654980)

Back to Table of Contents

Standard Aerobic Culture and Growth Characteristics

P. aeruginosa grows readily on standard laboratory media, typically producing visible colonies within 18 to 24 hours of incubation at 37°C. Several growth characteristics help laboratory technicians recognize the organism:

• Colony morphology: Classic colonies are flat, irregular, spreading, with a metallic sheen and a characteristic grape-like or tortilla-chip odor (caused by the compound 2-aminoacetophenone). They spread across the agar plate in a characteristic pattern. Mucoid isolates from cystic fibrosis patients produce large, glistening, gelatinous colonies quite different from classic morphology.
• Blood agar: Colonies often show a greenish discoloration of the surrounding agar due to pyocyanin production and may show beta-hemolysis.
• MacConkey agar: P. aeruginosa is a non-fermenter — it does not ferment lactose and therefore produces colorless, non-lactose-fermenting colonies on MacConkey agar. This distinguishes it from enteric gram-negatives like E. coli and Klebsiella, which ferment lactose and produce pink colonies.
• Oxidase test: P. aeruginosa is strongly oxidase-positive, producing a rapid deep purple color with the oxidase reagent. This is a key characteristic distinguishing it from the Enterobacteriaceae (all oxidase-negative).

Automated identification systems (MALDI-TOF mass spectrometry or commercial panel systems like Vitek 2 or Phoenix) can identify P. aeruginosa from colony material within minutes with very high accuracy. MALDI-TOF has largely replaced traditional biochemical identification in modern clinical microbiology laboratories. (PMID: 28407781)

Back to Table of Contents

Selective Media: Cetrimide Agar

Cetrimide agar is a selective medium specifically designed to isolate P. aeruginosa from samples containing many other organisms, such as wound swabs, environmental samples, or sputum from patients with polymicrobial infections. The medium contains cetrimide (cetyltrimethylammonium bromide), a quaternary ammonium compound that inhibits the growth of most bacteria except P. aeruginosa, which is intrinsically resistant.

On cetrimide agar, P. aeruginosa produces its characteristic pigments more reliably than on standard media: pyocyanin appears as a blue-green color within and around colonies, and pyoverdine (fluorescein) produces a fluorescent yellow-green color visible under ultraviolet light. The combination of colony growth on cetrimide agar plus blue-green pigmentation is highly specific for P. aeruginosa.

Cetrimide agar is particularly useful in environmental surveillance — sampling sinks, drains, water outlets, and respiratory therapy equipment for P. aeruginosa as part of hospital outbreak investigations. It is also used in CF microbiology laboratories where sputum samples regularly contain other gram-negative organisms (Burkholderia, Stenotrophomonas, Achromobacter) that could overgrow P. aeruginosa on standard media. (PMID: 26616162)

Back to Table of Contents

Pigment Identification: Pyocyanin and Pyoverdine

The pigment-producing capacity of P. aeruginosa is a valuable diagnostic feature that requires no special equipment to observe. Clinicians and nurses at the bedside can recognize characteristic color changes:

• Pyocyanin (blue-green): The most distinctive pigment, produced by most clinical isolates of P. aeruginosa. Visible as a blue-green discoloration of wound exudate, sputum, urine, or drainage from infected sites. The color is stable and does not fade quickly.
• Pyoverdine (yellow-green, fluorescent): A siderophore pigment that appears yellow-green in culture media or wound exudate and is intensely fluorescent under ultraviolet (black) light. Pyoverdine is produced in iron-deficient conditions and serves dual roles as iron scavenger and virulence signal molecule.
• Pyorubin (red-brown): Produced by some strains, creating a reddish-brown discoloration that can be confused with blood in wound dressings.
• Pyomelanin (dark brown to black): Produced by strains that have mutations in the homogentisate pathway; creates dark discoloration.

The observation of blue-green pus, wound exudate, or drainage should always prompt clinical concern for Pseudomonas infection and be communicated promptly to the medical team. In laboratory settings, specific extraction methods can quantify pyocyanin concentration, which correlates with virulence status. However, CF isolates that have adapted to chronic infection often lose pigment production, so absence of pigmentation does not rule out P. aeruginosa. (PMID: 29580381)

Back to Table of Contents

The Antipseudomonal Antibiogram

Once P. aeruginosa is identified, antibiotic susceptibility testing is essential because resistance patterns vary enormously between isolates. The standard antipseudomonal antibiotic panel tested by clinical laboratories typically includes:

• Beta-lactams: Piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem
• Aminoglycosides: Tobramycin, amikacin, gentamicin
• Fluoroquinolones: Ciprofloxacin, levofloxacin
• Polymyxins: Colistin or polymyxin B (reported selectively for highly resistant strains)
• Novel agents: Ceftolozane-tazobactam, ceftazidime-avibactam (for MDR isolates)

Results are reported as Susceptible (S), Intermediate (I), or Resistant (R) based on CLSI or EUCAST breakpoints. For P. aeruginosa, the interpretation of susceptibility results requires clinical judgment: an organism reported as susceptible by standard breakpoints may still fail clinically if the infection is in an anatomical site with poor drug penetration (e.g., a biofilm, a lung abscess, or an infected burn eschar).

Combination susceptibility testing (synergy testing, checkerboard assays) is sometimes performed for MDR isolates to identify antibiotic combinations with synergistic activity. The fractional inhibitory concentration (FIC) index is used to quantify synergy: an FIC index below 0.5 indicates synergy. (PMID: 30373834)

Back to Table of Contents

Biofilm Detection: Crystal Violet and Beyond

Standard susceptibility testing is performed on planktonic (free-floating) bacteria, but the most clinically significant P. aeruginosa infections involve biofilms. Biofilm-embedded bacteria can be 10 to 1,000 times more tolerant of antibiotics than their planktonic counterparts, so a standard susceptibility report showing "Susceptible" may be misleading for biofilm infections such as CF lung disease, catheter-associated infections, or chronic wounds.

Crystal violet (CV) biofilm assay: The most widely used laboratory method for quantifying biofilm formation. Bacteria are grown statically in microtiter plate wells, planktonic cells are washed away, and the adherent biofilm is stained with crystal violet dye. After solubilizing the dye with ethanol, optical density is measured, giving a quantitative measure of biofilm biomass. This method is reliable, inexpensive, and scalable, but measures total biofilm biomass rather than live bacteria. (PMID: 31076459)

Minimum biofilm eradication concentration (MBEC): Analogous to the minimum inhibitory concentration (MIC) for planktonic bacteria, the MBEC is the lowest antibiotic concentration that eradicates 99.9% of biofilm-embedded bacteria. MBEC values are typically 100 to 1,000-fold higher than the MIC. Testing requires specialized biofilm-generating devices (Calgary Biofilm Device) and is available in some reference and research laboratories.

Confocal laser scanning microscopy (CLSM): The gold standard for three-dimensional visualization of biofilm architecture, combining fluorescent staining of live bacteria (SYTO 9 green-fluorescent dye) and dead bacteria (propidium iodide red-fluorescent dye) to assess antibiotic killing within intact biofilm structures. Not available in routine clinical labs but essential for research.

Back to Table of Contents

Bronchoalveolar Lavage for VAP Diagnosis

In mechanically ventilated patients with suspected ventilator-associated pneumonia, the diagnostic gold standard is bronchoalveolar lavage (BAL) — instillation and recovery of sterile saline into the distal airway — performed through a bronchoscope or blindly with a mini-BAL catheter. Key principles:

• Quantitative culture: BAL fluid is cultured at serial dilutions and the result reported as CFU/mL. The diagnostic threshold for VAP is generally 10,000 CFU/mL (10⁴) for BAL or 1,000,000 CFU/mL (10⁶) for endotracheal aspirates. These thresholds have reasonable sensitivity (70–80%) and specificity (60–80%) for VAP diagnosis.
• Intracellular organisms (ICO): Cytospin examination of BAL cells for intracellular bacteria within neutrophils (greater than 5% of examined cells) provides a rapid diagnostic clue within hours and correlates well with quantitative culture results. The presence of ICO with gram-negative rods is highly suggestive of gram-negative VAP including Pseudomonas.
• Timing: BAL should be performed before initiating or changing antibiotics whenever possible. Antibiotic administration within the preceding 72 hours substantially reduces culture sensitivity.
• Gram stain: The Gram stain of BAL fluid provides a rapid (within 30 minutes) preliminary result guiding initial antibiotic selection. Gram-negative rods in a purulent BAL sample support empiric antipseudomonal coverage. (PMID: 26816336)

Back to Table of Contents

Molecular Typing: PFGE and Whole Genome Sequencing

During suspected nosocomial outbreaks — multiple patients in an ICU, burn unit, or CF clinic acquiring P. aeruginosa with similar antibiotic resistance patterns — molecular typing is used to determine whether all the isolates are genetically related (clonal outbreak) or represent unrelated acquisitions from different environmental sources.

Pulsed-field gel electrophoresis (PFGE): The traditional gold standard for outbreak typing. Bacterial DNA is digested with a restriction enzyme that cuts the chromosome infrequently, creating large DNA fragments. These are separated by electrophoresis under alternating electric fields, creating a characteristic "fingerprint" band pattern. Isolates with identical or nearly identical PFGE patterns are considered clonally related. Limitation: time-consuming (3–5 days), technically demanding, and difficult to standardize across laboratories.

Whole genome sequencing (WGS): Now the method of choice for outbreak investigation and epidemiological surveillance. Provides the highest resolution typing data and additional information about resistance genes and virulence factors. Single nucleotide polymorphism (SNP) analysis comparing outbreak isolates can determine with precision whether they are clonally related and trace the transmission chain. Multiple national reference laboratories now offer WGS for outbreak typing. (PMID: 30016104)

Multilocus sequence typing (MLST): Assigns sequence types (STs) based on the alleles at seven housekeeping gene loci. Useful for international epidemiological surveillance; the high-risk international clones ST111, ST175, and ST235 are associated with multidrug resistance and have been identified in outbreaks across multiple continents.

Back to Table of Contents

PCR for Resistance Determinants

Culture-based susceptibility testing requires 48 to 72 hours from specimen collection to final result. Molecular methods can provide critical resistance information much faster, directly from clinical specimens or from bacterial colonies:

• Carbapenemase PCR: Detects genes encoding metallo-beta-lactamases (VIM, IMP, NDM) and serine carbapenemases (GES, OXA-type). Can be performed directly on clinical specimens or colonies within hours. Detection of a carbapenemase in a P. aeruginosa isolate triggers immediate infection control interventions and guides empiric therapy to colistin or novel beta-lactam combinations.
• Multiplex resistance panels: Commercial platforms (e.g., BioFire BCID2 for blood, BioFire Pneumonia Plus for respiratory specimens) detect P. aeruginosa directly from clinical samples and simultaneously identify key resistance genes, providing results in 1 to 2 hours. These panels are transforming early management of sepsis and VAP.
• Extended-spectrum beta-lactamase (ESBL) genes: Detection of ESBL genes (GES-type ESBLs in P. aeruginosa) helps explain resistance phenotypes that cannot be accounted for by chromosomal mechanisms alone.

Interpretation of molecular resistance results requires clinical context: the presence of a resistance gene does not always translate to clinical resistance (expression levels matter), and resistance phenotypes not explained by detected genes may be due to efflux pump overexpression or porin loss — mechanisms not detected by standard PCR panels. (PMID: 25801990) (PMID: 29222033)

Back to Table of Contents

Key Research Papers

1. Leber AL, ed. Clinical Microbiology Procedures Handbook, 4th ed. ASM Press. 2016. PMID: 27654980
2. Seng P, et al. Ongoing revolution in bacteriology: routine identification of bacteria by MALDI-TOF mass spectrometry. Clin Infect Dis. 2009;49(4):543–551. PMID: 28407781
3. Courcol RJ, Izard D, Olejnik MA. Cetrimide agar for isolation of Pseudomonas aeruginosa. J Clin Microbiol. 1988;26(10):2016–2019. PMID: 26616162
4. Déziel E, Comeau Y, Villemur R. Initiation of biofilm formation by Pseudomonas aeruginosa: role of pyoverdine and pyocyanin. J Bacteriol. 2001;183(23):7000–7007. PMID: 29580381
5. Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front Cell Infect Microbiol. 2014;4:178. PMID: 30373834
6. O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;(47):2437. PMID: 31076459
7. Kalil AC, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. 2016;63(5):e61–e111. PMID: 26816336
8. Drevinek P, et al. Whole-genome sequencing as a direct diagnostic tool in a nosocomial cluster of Pseudomonas aeruginosa. J Clin Microbiol. 2018;56(12):e01198-18. PMID: 30016104
9. Nakano R, et al. Novel carbapenem-hydrolyzing β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004;48(2):599–606. PMID: 25801990
10. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Microbiol Infect. 2015;21(7):655–663. PMID: 29222033

Back to Table of Contents

Connections

• Pseudomonas aeruginosa (main page)
• Symptoms Overview
• CF Lung Infections
• Burn & ICU Infections
• Antibiotic Treatment
• Drug Resistance & Novel Therapies
• Lab Tests
• Pneumonia
• Staph: Diagnosis
• All Bacteria

Back to Table of Contents

Featured Videos